BIIB FY 2022 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

FY 2022 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$10.2B-7.4% YoY

Gross Profit

$7.9B77.6% margin

Operating Income

$2.9B28.4% margin

Net Income

$3.0B29.9% margin

EPS (Diluted)

$20.87

Cash Flow

Operating Cash Flow

$1.4B

Free Cash Flow

$1.1B

Stock-Based Comp.

$254M

Balance Sheet

Total Assets

$24.6B

Total Liabilities

$11.2B

Stockholders' Equity

$13.4B

Cash & Equivalents

$3.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10.2B	$11.0B	-7.4%
Gross Profit	$7.9B	$8.9B	-11.0%
Operating Income	$2.9B	$2.8B	+3.5%
Net Income	$3.0B	$1.6B	+95.8%